All In Biotech

Drug Trial Radar · NCT01633112

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: May 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,064 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,064

Actual

Start

Aug 9, 2012

Primary completion

Apr 30, 2018

Study completion Apr 30, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS

Conditions

  • Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions

  • fingolimodDrug

    capsule

  • glatiramer acetateDrug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Annualized Relapse RateTime frame: up to 12 months

Locations

130 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Cullman, Alabama

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Boulder, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Loveland, Colorado

  • Novartis Investigative Site

    Fairfield, Connecticut

  • Novartis Investigative Site

    Newark, Delaware

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Maitland, Florida

  • Novartis Investigative Site

    Naples, Florida

  • Novartis Investigative Site

    New Port Richey, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Ormond Beach, Florida

  • Novartis Investigative Site

    Pompano Beach, Florida

  • Novartis Investigative Site

    Ponte Vedra Beach, Florida

  • Novartis Investigative Site

    Port Charlotte, Florida

  • Novartis Investigative Site

    Sarasota, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Vero Beach, Florida

  • Novartis Investigative Site

    West Palm Beach, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Elk Grove Village, Illinois

  • Novartis Investigative Site

    Evanston, Illinois

  • Novartis Investigative Site

    Flossmoor, Illinois

  • Novartis Investigative Site

    Northbrook, Illinois

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    West Des Moines, Iowa

  • Novartis Investigative Site

    Kansas City, Kansas

  • Novartis Investigative Site

    Lenexa, Kansas

  • Novartis Investigative Site

    Louisville, Kentucky

Showing 40 of 130 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.